The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company has raised US$4.5 million in funding for its AI operating system
Subscribe To Our Newsletter & Stay Updated
